Caris Life Sciences Management
Management criteria checks 3/4
Caris Life Sciences' CEO is David Halbert, appointed in Jan 2008, has a tenure of 18.58 years. total yearly compensation is $20.35M, comprised of 3.8% salary and 96.2% bonuses, including company stock and options. directly owns 43.39% of the company’s shares, worth $3.01B. The average tenure of the management team and the board of directors is 6.3 years and 13.5 years respectively.
Key information
David Halbert
Chief executive officer
US$20.4m
Total compensation
| CEO salary percentage | 3.76% |
| CEO tenure | 18.6yrs |
| CEO ownership | 43.4% |
| Management average tenure | 6.3yrs |
| Board average tenure | 13.5yrs |
Recent management updates
Recent updates
CAI: Q2 Execution And Buybacks Will Support Balanced Future Prospects
Analysts have raised their price target for Caris Life Sciences from $21.00 to $22.00 as they adjust their models based on updated assumptions regarding revenue growth, profit margins, the discount rate, and future P/E expectations. What’s in the News for Caris Life Sciences Caris Life Sciences reported second quarter 2026 financial results, with 45% revenue growth driven by molecular profiling services and approximately 59,200 clinical cases completed.Caris Life Sciences: Guidance Raised, Valuation Still Attractive
Summary Caris Life Sciences delivered another strong quarter, raising full-year guidance and expanding margins while sustaining positive free cash flow. Accelerating clinical volume growth and the commercial launch of Caris Detect reinforce the durability and breadth of CAI's growth drivers. Valuation remains attractive and CAI trades at a discount to peers, with a fair value estimate of $30 per share by 2028. I reiterate my Buy rating, citing robust revenue growth, improving profitability, and long-term optionality despite rising expectations. Read the full article on Seeking Alpha
CAI: Early Detection Sequencing Platform Will Drive Future Upside Potential
Analysts have reduced their price target for Caris Life Sciences to $27.00 from $38.11, citing updated assumptions for lower revenue growth, narrower profit margins, and a slightly higher discount rate that together indicate a less optimistic P/E outlook. What's in the News for Caris Life Sciences Caris Life Sciences launched in-house PTEN immunohistochemistry testing to help identify patients with PTEN-deficient metastatic prostate cancer who may be eligible for a recently FDA approved biomarker guided therapy and companion diagnostic assay.
CAI: Early Cancer Detection Advances Will Support A Stronger Long-Term Outlook
The analyst price target for Caris Life Sciences has shifted from $45.00 to approximately $36.00 as analysts apply a slightly higher discount rate and more moderate assumptions for revenue growth, profit margin, and future P/E. What’s in the News for Caris Life Sciences Caris Life Sciences launched Caris Detect, a multi cancer early detection blood test that uses ultra deep Whole Genome and Whole Transcriptome sequencing with AI to analyze a wide range of molecular and biological cancer signals.CAI: Strong Q1 Execution And Buyback Will Support Future Upside
Analysts have revised their price target on Caris Life Sciences to $21.00 from $26.23, citing updated assumptions that combine lower projected revenue growth with slightly higher expected profit margins and a reduced future P/E multiple. What’s in the News for Caris Life Sciences Caris Life Sciences reported Q1 2026 results with revenue rising 79%, molecular profiling revenue rising 85%, gross margin expansion, and positive Adjusted EBITDA and free cash flow, as the company positions itself as an AI-enabled precision oncology and molecular diagnostics platform (source: recent earnings coverage).Whole Genome Push Will Strain Margins Yet Could Eventually Support A Stronger Future
Catalysts About Caris Life Sciences Caris Life Sciences provides comprehensive molecular profiling and data-driven precision medicine solutions across tissue and blood for oncology and related applications. What are the underlying business or industry changes driving this perspective?Caris Life Sciences, Inc.'s (NASDAQ:CAI) Shares May Have Run Too Fast Too Soon
There wouldn't be many who think Caris Life Sciences, Inc.'s ( NASDAQ:CAI ) price-to-sales (or "P/S") ratio of 9.5x is...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$105m |
| Mar 31 2026 | n/a | n/a | -US$411m |
| Dec 31 2025 | US$20m | US$765k | -US$538m |
| Sep 30 2025 | n/a | n/a | -US$682m |
| Jun 30 2025 | n/a | n/a | -US$799m |
| Mar 31 2025 | n/a | n/a | -US$371m |
| Dec 31 2024 | US$2m | US$750k | -US$378m |
Compensation vs Market: David's total compensation ($USD20.35M) is above average for companies of similar size in the US market ($USD8.27M).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Halbert (70 yo)
Dr. David Dean Halbert, M.D., DSc (h.c.) Founded Caris, Ltd. in 2005 and serves as its General Partner. Dr. Halbert serves as the Chairman, Founder and Chief Executive Officer at U.S.Caris MPI, Inc. (d/b/...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 18.6yrs | US$20.35m | 43.39% $ 3.0b | |
| Executive Vice Chairman & Executive VP | 8.6yrs | no data | 0.19% $ 13.5m | |
| President | 9.8yrs | US$11.58m | 0.19% $ 13.0m | |
| Senior VP | 3.9yrs | US$5.35m | 0.018% $ 1.3m | |
| Senior VP | 9.3yrs | no data | 0.0054% $ 376.5k | |
| Senior VP & Chief Operations Officer | 3.6yrs | no data | no data | |
| Senior VP & CTO | no data | no data | no data | |
| Senior VP & Chief Scientific Officer | 3.6yrs | no data | no data | |
| Senior Vice President of Human Resources & Chief Compliance Officer | less than a year | no data | no data | |
| Senior Vice President of Corporate Development | no data | no data | no data | |
| Executive VP & Chief of Staff at Office of the CEO | no data | no data | no data | |
| Senior VP & Chief Innovation Officer | no data | no data | no data |
Experienced Management: CAI's management team is seasoned and experienced (6.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 14.8yrs | US$20.35m | 43.39% $ 3.0b | |
| Executive Vice Chairman & Executive VP | 8.6yrs | no data | 0.19% $ 13.5m | |
| Lead Independent Director | 18.6yrs | US$647.34k | 3.69% $ 256.4m | |
| Director | 12.3yrs | US$350.00k | 0.51% $ 35.5m | |
| Independent Director | 18.6yrs | US$359.00k | 0.11% $ 7.7m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 11yrs | US$412.06k | 0.037% $ 2.5m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
Experienced Board: CAI's board of directors are seasoned and experienced ( 13.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/21 03:31 |
| End of Day Share Price | 2026/08/20 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Caris Life Sciences, Inc. is covered by 18 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Bamberger | Baird |
| Catherine Ramsey Schulte | Baird |
| Michael Ryskin | BofA Global Research |